ENDOCRINE PUBLICATIONS & ABSTRACTS
Endocrine data
Evidence / Endocrine
Differential Long-Term Benefit of 2-Year Adjuvant Tamoxifen Therapy for Luminal-Type Breast Cancer: Insights From a 20-Year Follow-Up Analysis of the STO Trials
Publication: ESMO Annals of Oncology, Breast cancer, early stage, Volume 35, Supplement 2S346, September 2024 Authors: M. Rios Romero, O. Danielsson, T. Fornander, A. Nordenskjöld, G. Pérez Tenorio, N.P. Tobin, B.A. Nordenskjöld, O. Stål, L. Esserman, L.J. Van't Veer, L.S. Lindström Title: Differential long-term benefit of 2-year adjuvant tamoxifen Read More
Gene-expression assays to tailor adjuvant endocrine therapy
Clinical Cancer Research, Vol 30, Issue 14, July 15 2024 Author: Bottosso et al.
Read MoreGene Expression assays to tailor adjuvant endocrine therapy
Clinical Cancer Research OF1–OF11, May 2024 Author: Bottosso et al.
Read MoreMammaPrint UltraLow from FLEX Study, Graham et al., SABCS 2023 Abstract
SABCS 2023, PO1-02-11 Authors: Cathy Graham et al.
Read MoreLESS: Single-arm study to de-escalate adjuvant endocrine therapy duration in post-menopausal women with HR+ HER2- breast cancer at very low risk of metastasis
Publication: ASCO 2023, Abstract TPS615 Authors: Elise Deluche, Stefan Michiels, Daniele Fric, Christophe Perrin, Caroline Bailleux, Thomas Bachelot, Pascal Ko Kivok Yun, Gaetan De Rauglaudre, Marie-Ange Mouret-Reynier, Romauld Le Scodan, Ines Vaz-Luis, Magali Lacroix-Triki, Clara Guyonneau, Fabrice Andre
Read MoreFOCUS Trial: Validation of MammaPrint for ≥ 70yrs w/ UltraLow risk of distant recurrence
J Geriatr Oncol. 2022 Nov;13(8):1172-1177 Authors: Noordhoek et al.
Read MoreIKA Trial: MammaPrint UltraLow & Limited Systemic Endocrine Overtreatment
IKA Trial, Breast Cancer Res Treat, 2022; 194(2): 265-278 Authors: Opdam, et al.
Read More
